Investor Protection Investor Damages Misleading Information Disclosure Obligations Market Regulation Misrepresentation Material Information Misleading Statements Market Impact
The lawsuit alleges undisclosed weaknesses in third‑party manufacturing controls that put briquilimab trial readouts at risk of being confounded.